The recently developed Open Targets platform consolidates a wide range of 
comprehensive evidence associating known and potential drug targets with human 
diseases. We have harnessed the integrated data from this platform for novel 
drug repositioning opportunities. Our computational workflow systematically 
mines data from various evidence categories and presents potential repositioning 
opportunities for drugs that are marketed or being investigated in ongoing human 
clinical trials, based on evidence strength on target-disease pairing. We 
classified these novel target-disease opportunities in several ways: (i) number 
of independent counts of evidence; (ii) broad therapy area of origin; and (iii) 
repositioning within or across therapy areas. Finally, we elaborate on one 
example that was identified by this approach.